Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by canadapieton Aug 12, 2019 9:21am
100 Views
Post# 30017385

RE:RE:RE:Nasdaq Listing announcements

RE:RE:RE:Nasdaq Listing announcementsFor now, it is a "poor offer" Nasdaq listing!!
There are much better companies/possibilities in the biotech Nasdaq space! 
That can change however if they have a good folow-up news/ announcements in the near (really near) future. And i hope they have, it would show finally good management behavior! 
(new Egrifta and especially Nash......, and why not something coming out of our "Katana"........).

Hoping again and again and again......


"SPCEO wrote: 
The real change is that it will be much easier for US retail and Institutional investors to buy the stock. Brokers don't want their clients to buy OTC stocks in the US because the OTC exchange is viewed as a dangerous place. Something called "blue sky" laws prevented many retail investors from buying THERF in many US states. THERF shares counted for nothing in a margin account. All that nonsense will now go away. 
longterm56 wrote:What happens to the shares traded in the US under the symbol "THERF" ?  Do these become identical TH shares?

  -LT

palinc2000 wrote:Dubuc was the only one during the July 11 th CC to mention anything about the Naz Listing(bod approval)
This morning ‘s announcement is also made by Dubuc only...
This is odd....

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities